Belimumab for early lupus activity in the first two years
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) and it was diagnosed within the last 2 years
- Your blood tests show ANA positive and anti–double-stranded DNA (anti-dsDNA) positive
- Your lupus activity is mild to moderate (SLEDAI-2K score of 4 or higher)
- Your steroid dose is stable and not too high (30 mg per day or less) for the past 4 weeks
- You take hydroxychloroquine unless you cannot tolerate it
- If you could become pregnant, you must have a negative pregnancy test and use birth control during treatment and for 16 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This study is building a national biobank (a storage of blood and health information) to learn more about lupus in people who were recently diagnosed (within the last 2 years). It's for patients whose lupus is not causing serious damage to major organs, so that researchers can study how the disease behaves early on.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.